GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » Forward PE Ratio

Angion Biomedica (Angion Biomedica) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica Forward PE Ratio?

Angion Biomedica's Forward PE Ratio for today is 0.00.

Angion Biomedica's PE Ratio without NRI for today is 0.00.

Angion Biomedica's PE Ratio for today is 0.00.


Angion Biomedica Forward PE Ratio Historical Data

The historical data trend for Angion Biomedica's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica Forward PE Ratio Chart

Angion Biomedica Annual Data
Trend
Forward PE Ratio

Angion Biomedica Quarterly Data
Forward PE Ratio

Competitive Comparison of Angion Biomedica's Forward PE Ratio

For the Biotechnology subindustry, Angion Biomedica's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Angion Biomedica's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Angion Biomedica's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Angion Biomedica's Forward PE Ratio falls into.



Angion Biomedica Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Angion Biomedica  (NAS:ANGN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Angion Biomedica Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Angion Biomedica (Angion Biomedica) Business Description

Traded in Other Exchanges
N/A
Address
7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Executives
Jay Venkatesan director, officer: See Remarks C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan officer: See Remarks 750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan officer: See Remarks 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes officer: See Remarks C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg officer: See Remarks 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi director
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc 10 percent owner C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553